Exploring the Evolving Significance of lncRNA TUG1-mediated Signaling Pathways in Breast Cancer

Q3 Medicine Current Signal Transduction Therapy Pub Date : 2024-01-19 DOI:10.2174/0115743624264761231212055008

Mahrokh Abouali Gale Dari, Amir Anbiyaiee, M. Moghanibashi, R. Mohammad Jafari, F. Moramezi, Maryam Farzaneh

{"title":"Exploring the Evolving Significance of lncRNA TUG1-mediated Signaling\nPathways in Breast Cancer","authors":"Mahrokh Abouali Gale Dari, Amir Anbiyaiee, M. Moghanibashi, R. Mohammad Jafari, F. Moramezi, Maryam Farzaneh","doi":"10.2174/0115743624264761231212055008","DOIUrl":null,"url":null,"abstract":"\n\nBreast cancer is one of the most common malignancies in women worldwide. Invasive\nductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common kinds\nof invasive breast cancer. Several genetic, epigenetic, and environmental factors could trigger\nthe pathogenesis of breast cancer. Breast cancer treatment generally includes surgery, radiation\ntherapy, chemotherapy, hormonal treatment, targeted therapy, immunotherapeutic, neoadjuvant\nsystemic therapy, and systemic therapy. Although several classical treatment methods are used\nin cancer therapy, molecular-based strategies can open a new perspective for breast cancer\ntreatment. Previous studies reported that long non-coding RNAs (lncRNAs) play important roles\nin cancer development and progression. LncRNA TUG1 was found to target several miRNAs\nand regulate breast cancer cell behavior. TUG1 can induce cell proliferation and invasion of\nbreast cancer cells via downregulation of some miRNAs. Therefore, TUG1 might be a potent\nbiomarker for the treatment of human cancer. In this review, we summarized the functional roles\nof TUG1 in breast cancer.\n","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":"15 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Signal Transduction Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115743624264761231212055008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is one of the most common malignancies in women worldwide. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common kinds of invasive breast cancer. Several genetic, epigenetic, and environmental factors could trigger the pathogenesis of breast cancer. Breast cancer treatment generally includes surgery, radiation therapy, chemotherapy, hormonal treatment, targeted therapy, immunotherapeutic, neoadjuvant systemic therapy, and systemic therapy. Although several classical treatment methods are used in cancer therapy, molecular-based strategies can open a new perspective for breast cancer treatment. Previous studies reported that long non-coding RNAs (lncRNAs) play important roles in cancer development and progression. LncRNA TUG1 was found to target several miRNAs and regulate breast cancer cell behavior. TUG1 can induce cell proliferation and invasion of breast cancer cells via downregulation of some miRNAs. Therefore, TUG1 might be a potent biomarker for the treatment of human cancer. In this review, we summarized the functional roles of TUG1 in breast cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索lncRNA TUG1介导的信号通路在乳腺癌中不断演变的意义

乳腺癌是全球妇女最常见的恶性肿瘤之一。浸润性导管癌（IDC）和浸润性小叶癌（ILC）是最常见的浸润性乳腺癌。多种遗传、表观遗传和环境因素可能诱发乳腺癌的发病机制。乳腺癌的治疗一般包括手术、放疗、化疗、激素治疗、靶向治疗、免疫治疗、新辅助系统治疗和全身治疗。尽管癌症治疗中使用了多种经典治疗方法，但基于分子的治疗策略可以为乳腺癌的治疗开辟一个新的视角。以往的研究表明，长非编码 RNA（lncRNA）在癌症的发生和发展中发挥着重要作用。研究发现，LncRNA TUG1以多种miRNA为靶标，调控乳腺癌细胞的行为。TUG1 可通过下调某些 miRNAs 诱导乳腺癌细胞增殖和侵袭。因此，TUG1 可能是治疗人类癌症的有效生物标记物。在这篇综述中，我们总结了 TUG1 在乳腺癌中的功能作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Signal Transduction Therapy 医学-药学

CiteScore

1.70

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders. The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.